Abstract: Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.

Abstract: A process for treating a polysaccharide with a dialdehyde in the presence of from 10 to 40 weight percent of water, based on the total weight of polysaccharide and water, is beneficially conducted in a mixing device characterized by a FROUDE number FRw of larger than 11, wherein ?w is the angular frequency in sec-1 and is defined as 2*?*RPM/60, RPM is the rotational speed of the mixing device in revolutions per minute, Rw is the radius of the mixing device in m, and g is the acceleration due to gravity in m/s2.

Abstract: The present invention relates to soft pastilles for nicotine replacement therapy, said pastille comprises about 0.05% to about 1% of nicotine active; about 5% to about 40% of gelling agent; about 30% to about 70% of plasticizer; about 0.05% to about 10% of sweetener; 0.5% to about 30% of releasing agent; about 0.05% to about 2% of preservative; about 0.01% to 5% of flavoring agent; and about 5% to about 20% of water.

Abstract: A salt-free emulsion for the treatment of dry eye and other ocular conditions is disclosed which contains castor oil and does not contain olive oil which prolongs TBUT and provides superior comfort.

Abstract: A biocellulose dressing contains a high content of a humectant with superior absorbency and promotes wound healing. The biocellulose dressing contains 10-20% (w/w) of water, 5-30% (w/w) of a microbial cellulose and 50-80% (w/w) of a humectant. A method for preparing dressing is also disclosed.

Abstract: A termite bait includes a plurality of cellulosic food material pieces palatable to termites embedded within a water resistant polyurethane foam matrix. Another termite bait includes a plurality of cellulosic food material pieces embedded within a water-absorbent polyurethane foam matrix. Yet another termite bait includes at least one cellulosic food material piece encapsulated within a water resistant polyurethane foam coating. Such termite baits can be used alone or in a monitoring device or other termite control device. Another termite control device includes a container, a cellulosic food material within the container and a water resistant polyurethane foam positioned to separate the food material from its environment. The container can contain a termite bait as described above or can include a chamber containing a cellulosic food material and at least one pocket containing a polyurethane foam barrier to reduce intrusion of water through the pocket to the food material.

Abstract: The invention provides a cellulose derivative having a repeating unit of the formula below, a composition including the cellulose derivative and a phospholipid, a method for production thereof, and an adhesion barrier including the cellulose derivative or the composition. In the formula, R1, R2, and R3 are —H, —CH2—COOH, —CH2—COOX, or —CH2CO-phosphatidylethanolamine, and X is an alkali metal or an alkali earth metal. The degree of substitution of —CH2—COOH and —CH2—COOX is 0.3 to 2.0 in total, and the degree of substitution of —CH2CO-phosphatidylethanolamine is 0.001 to 0.05.

Abstract: A process is disclosed for obtaining citrus fiber from citrus pulp. Citrus fiber is obtained having a c* close packing concentration value of less than 3.8. The citrus fiber can be obtained having a viscosity of at least 1000 mPa·s, wherein said citrus fiber is dispersed in standardized water at a mixing speed of from 800 rpm to 1000 rpm, to a 3 w/w % citrus fiber/standardized water solution, and wherein said viscosity is measured at a shear rate of 5 s?1 at 20° C. Citrus fiber can be obtained having a CIELAB L* value of at least 90. The citrus fiber can be used in food products, feed products, beverages, personal care products, pharmaceutical products or detergent products.

Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.

Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency which demonstrate excellent water resistance. The compositions are useful as mechanical hemostatic tamponades for the control of osseous hemorrhage. The compositions comprise carboxymethyl cellulose and one or more compounds selected from polyhydroxy compounds, esters of polyhydroxy compounds, fatty acids, esters of fatty acids, and mixtures of the foregoing.

Abstract: The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.

Abstract: The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.

Abstract: A method of providing hemostasis of bleeding tissue. A flexible bioresorbable foam is formed that consists essentially of carboxymethylcellulose. The flexible bioresorbable foam is crosslinked. Chain scission is performed on the crosslinked flexible bioresorbable foam to provide the flexible bioresorbable foam with a selected in-vivo residence time of between about 3 days and about 14 days. Hemostasis is caused by applying the flexible bioresorbable foam to bleeding tissue. The flexible bioresorbable foam is resorbed in-vivo. The selected in-vivo residence time is a time between the flexible bioresorbable foam being applied to the tissue and the flexible bioresorbable foam having been substantially completely absorbed into the tissue.

Abstract: A preparation for use in the treatment of clostridium difficile or salmonella infection comprising a mixture of galacto-oligosaccharide and matter from cranberry, and uses thereof.

Abstract: Compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses are disclosed. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. The siloxane can have a hydrophilic group. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film. The compositions and kits, optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent. Such a film can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray.

Abstract: An orally administrable implement for expanding in a stomach of an animal, including a mammal, to fill a space in the stomach, is provided for weight control. The implement includes: a fluid-permeable expandable container having a first dimension and a second dimension; and a plurality of clusters comprising a swellable material contained within the container and capable of swelling when contacted with a fluid; whereby when the implement is ingested, the fluid in the stomach enters the container causing the clusters therein to swell and the container to expand from the first dimension to the second dimension.

Abstract: A cellulose derivative which has a suitable elastic modulus and viscosity when it is dissolved in water and is useful as an adhesion barrier. The cellulose derivative has a molecular weight of 5×103 to 5×106 and is composed of a repeating unit represented by the following formula (1): wherein R1, R2 and R3 are each independently selected from the group consisting of the following formulas (a), (b), (c) and (d) in predetermined amount: (X in the formula (c) is an alkali metal, and R4 and R5 in the formula (d) are each independently an alkyl group or alkenyl group having 10 to 28 carbon atoms).

Abstract: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions comprise a combination of an oxidized regenerated cellulose component and a non-steroidal anti-inflammatory drug (NSAID) which functions as an inhibitor of cyclooxygenase enzyme (Cox) activity. Such methods comprise administering an effective amount of the composition directly to the serosal surfaces of the gastrointestinal and other visceral organs.

Abstract: The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic film-forming polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of mucositis induced by radiation or chemotherapy.

Abstract: Provided are a novel carboxymethyl cellulose (CMC) structure and a method for producing the same. The CMC structure of the present invention is useful as a medical material and particularly as an adhesion-preventing material, and has good biocompatibility and bioabsorbability and controllable periods of functioning and dissolving, or has both effects for preventing adhesions and wound healing. The CMC structure of the present invention is substantially composed of carboxymethyl celluloses, comprising an acid carboxymethyl cellulose and an alkaline metal carboxymethyl cellulose in a mixed state. The method of production of the present invention comprises subjecting the alkaline metal (or acid) carboxymethyl cellulose structure to an acid (or alkali) treatment, wherein the acid (or alkali) treatment is terminated before the alkaline metal (or acid) carboxymethyl cellulose is fully converted to the acid (or alkaline metal) carboxymethyl cellulose.

Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.

Abstract: The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing amine and/or ammonium groups.

Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Abstract: This document provides complexes comprising a mineral-amino acid compound and a polysaccharide. For example, the document provides compositions containing such complexes and methods of making and using such complexes.

Abstract: An object is to provide a film preparation comprising a polymer harmless to living bodies and being highly adhesive to the skin; and a film preparation further containing a pharmaceutically active oily ingredient and being highly adhesive to the skin. More specifically, provided is a film preparation comprising a drug, a wetly shear-triturated low-substituted cellulose ether having a molar substitution of from 0.05 to 1.0 per anhydrous glucose unit, and a water-soluble cellulose ether, and having 100 minutes or greater of adhesion ability to the skin. The preparation becomes a skin-adhesive hydrous sheet having excellent skin adhesion after it is wet with water as it is used.

Abstract: The invention relates to dispersible cellulose powder compositions comprising non-seed cellulose powder derived from algae, fungi or tunicates, which compositions are useful in a variety of products such as food products, pharmaceuticals, cosmetics, paints, biocompatible materials for artificial tissue engineering and implantable biomaterials and relates to methods for preparing non-seed cellulose powder compositions.

Abstract: The present invention relates to a method for the preparation of 4-hyroxy-L-proline or compositions with a high content of this aminoacid and the use thereof as agrochemical in the agronomical field and/or as a synthesis intermediate of chemical compounds.

Abstract: The invention concerns: a silylated biomolecule having the following formula (I): the process for the preparation of a silylated biomolecule of formula (I), the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), the hydrogel obtainable by said process, said hydrogel as a biological tissue substitute, a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, said composition for the release of active principle.

Abstract: The invention relates to an injectable composition intended for tissue induction of the soft tissues by a system of immediate and prolonged progressive release. In particular, the invention relates to a composition comprising a gel of at least one first biodegradable polymer forming a first agent for filling soft tissues in an animal, and a suspension in this gel of microspheres with an average diameter between 5 and 50 micrometres, said microspheres comprising 50 to 90 wt. % of at least one biodegradable polysaccharide relative to the total weight of the microspheres, said microspheres inducing a second filling by tissue induction and containing at least one second biodegradable polymer forming at least one third filling of the soft tissues in an animal.

Abstract: A topical skin barrier for protecting and promoting healing of skin, and for providing comfort to a patient, comprises a semi-solid hydrocarbon and a water-absorbing compound. The topical skin barrier effectively adheres to skin, affords protection from moisture and waste, and provides transparency in use. Methods of in vitro evaluation are for (i) a composition's protection from moisture and waste, and (ii) a composition's adhesion to skin.

Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.

Abstract: An inhibiting heart failure disease pharmaceutical composition is provided. The pharmaceutical composition includes: an effective amount of a KMUP-3 amine salt of formula (I); wherein RX contains a carboxylic group donated from one selected from a group consisting of a sodium carboxyl methylcellulose (sodium CMC), a ?-polyglutamic acid derivative, and co-polymer salt; RX? is an anion form of the carboxylic group; and a pharmaceutically accepted carrier.

Abstract: Described herein are composites that inhibit or reduce adhesion between two or more tissues. Also described herein are methods of using the composites.

Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.

Abstract: The invention provides a flexible bioresorbable foam having hemostatic properties. The foam is formed from a carboxymethylcellulose suspension.

Abstract: A solid material adapted to kill bacteria in planktonic, spore and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The solid material includes a significant amount of one or more surfactants entrained in a crosslinked polymeric network.

Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Abstract: A physical mode of action pesticide for application on plants and in soils, and methods of manufacture and application, comprising an active ingredient in the form of a polymer in a concentration of less than 0.1% wt., a surfactant, a co-solvent and a diluent in a hydrocolloid suspension. The suspension polymer is preferably a polysaccharide having a molecular weight of 10,000 to 25,000,000, and preferably in the range of about 600,000. The pesticide preferably also includes a targeting ingredient for directing the active ingredient to a particular target.

Abstract: The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): wherein R2 and R4 are each selected independently from the group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom; RX contains a carboxylic group donated from one selected from a group consisting of a Statin, a Co-polymer, a poly-?-polyglutamic acid (?-PGA) derivative and sodium CMC; and ?RX substituent is an anion of the carboxylic group carrying a negative charge; and a pharmaceutically accepted carrier.

Abstract: Provided are methods of treating cardiac infarction by using an injectable material to influence cardiac structure and remodeling after infarction. Also provided are kits that comprise an injectable material to influence cardiac structure.

Abstract: A tissue thickness compensator may generally comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a third layer comprising a third medicament. The tissue thickness compensator may comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a reservoir comprising a third medicament disposed within the reservoir. The medicaments may be independently selected from a haemostatic agent, an anti-inflammatory agent, an antibiotic agent, anti-microbial agent, an anti-adhesion agent, an anti-coagulant agent, a pharmaceutically active agent, a matrix metalloproteinase inhibitor, and combinations thereof. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.

Abstract: A pharmaceutical composition comprises a polyethylene glycol having a molecular weight in the range from about 1,000 to about 10,000, and a water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to 120,000. The composition can further comprise boric acid and/or phosphate, a non-ionic surfactant, and/or an ophthalmic therapeutic agent. The composition is effective in treating, controlling, ameliorating, or reversing one or more conditions or symptoms of dry eye.

Abstract: The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40000 to 50000 g/mole, zero shear viscosity of more than 10 Pas, and pseudoplasticity of more than 20, obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. Said substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Abstract: Provided is an injectable composition for intra-articular administration including at least one viscosupplementation agent selected from hyaluronic acid, chondroitin sulphate, keratin, keratin sulphate, heparin, cellulose and derivatives thereof, for example, chitosan, xanthans, galactomannan, alginates, and one or more salts thereof, and a fibroblast growth medium. The viscosupplementation agent and the fibroblast growth medium can be provided in a single composition for injection or as separate components for simultaneous, separate, or subsequent injection over time.

Abstract: Hydrogel particles include: (A) a water-insoluble complex containing catechins; (B) a compound which forms chelate together with divalent or trivalent metal ions; (C) a divalent or trivalent metal salt; (D) a gel-forming agent; and (E) water.

Abstract: An object of the present invention is to provide an aqueous film coating solution, and the like, which has good acid resistance and sustained release properties as well as the flexibility suitable for the tablet compression force and are highly productive and cost efficient. The aqueous film coating solution of the present invention comprises an ethyl acrylate/methyl methacrylate copolymer dispersion, a methacrylic acid copolymer LD, a plasticizer, titanium oxide and water, wherein the solid mass ratio of the ethyl acrylate/methyl methacrylate copolymer dispersion, the methacrylic acid copolymer LD, the plasticizer and the titanium oxide is 100:(40 to 100):(5 to 50):(5 to 30) and the solid content thereof is 5 to 20 mass %.

Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Abstract: In one aspect, there is provided a compound comprising an acetylated carboxymethylcellulose (CMC-Ac) covalently linked to: at least one poly(ethylene glycol) (PEG), and at least one hydrophobic drug. In another aspect, a self-assembling nanoparticle composition comprising such compounds is provided.